The European Scientific Committee on Consumer Safety (SCCS) has issued its final opinion on butylated hydroxyanisole (BHA), the synthetic antioxidant long used across cosmetic, pharmaceutical and food formulations.

The opinion closes the scientific assessment phase of the Committee's review under the EU Cosmetics Regulation (EC) No 1223/2009. The European Commission requests SCCS opinions, which typically follow a draft opinion released for public consultation, during which manufacturers, safety assessors, member states and academic researchers submit toxicological, exposure and clinical data for the Committee's consideration.

What does a final SCCS opinion cover?

A final opinion sets out the Committee's consolidated scientific view on safe use, including any concentration thresholds, product-type restrictions, purity criteria or labelling warnings. Once adopted by the Commission, these conclusions feed into amendments to the Cosmetics Regulation's Annexes — most commonly Annex III, which lists substances with conditions of use, or Annex II, which lists prohibited substances.

The SCCS opinion format typically includes hazard identification, an exposure assessment specific to cosmetic use scenarios, margin-of-exposure calculations, and a final risk characterisation.

For widely used ingredients like BHA, the Committee also considers aggregate exposure across product categories, including rinse-off contributions from shampoo and cleanser systems that would otherwise be assessed separately.

For BHA, which the EU currently authorises as an antioxidant in cosmetic products under specified conditions and concentration ceilings, the final opinion will determine whether existing permitted levels and product-type carve-outs are maintained, adjusted or qualified with new restrictions.

Where does BHA fit in the broader review cycle?

The BHA review sits within the Commission's broader re-evaluation of cosmetic preservatives and antioxidants, several of which have come under renewed scrutiny over the past decade as exposure modelling has grown more sophisticated. Formulators combining multiple lipid-soluble antioxidants — a common approach in long-shelf-life products — should pay particular attention to aggregate exposure considerations, which the Committee increasingly weights in its risk characterisations.

Why does BHA matter to formulators?

BHA (INCI: Butylated Hydroxyanisole) delivers its value in lipid-heavy formulations — lipsticks, fragrance oils, anhydrous balms and certain cream systems — through carry-through antioxidant performance and synergy with butylated hydroxytoluene (BHT, INCI: BHT).

That functional profile has made BHA harder to substitute cleanly than water-soluble antioxidants. Common alternatives include mixed tocopherols, ascorbyl palmitate (INCI: Ascorbyl Palmitate) and rosemary extract (INCI: Rosmarinus Officinalis Leaf Extract), each of which typically requires rebalancing the full antioxidant system and may shift a formulation's natural-versus-synthetic positioning.

What does the opinion mean for professional treatment menus?

BHA appears in some leave-on professional skincare products — antioxidant serums, post-procedure balms and certain treatment oils — where any revised conditions of use could affect retail availability and salon procurement over the coming year. Spa and clinic buyers reviewing antioxidant lines should flag BHA-containing SKUs for re-evaluation once the Commission's implementing regulation is published.

What should compliance teams do?

Compliance teams responsible for Annex III declarations and Product Information Files (PIFs) should treat the publication of the final opinion as the trigger to reassess:

• Finished-product concentrations of BHA in current formulations
• Aggregate exposure calculations for leave-on and rinse-off products
• Any required label changes, particularly for products marketed across multiple jurisdictions

What to watch next?

The next concrete data point is publication of the full opinion text on the SCCS section of the European Commission's website, which will specify the Committee's recommended thresholds and any revised conditions of use.

Industry should then monitor the Commission for an implementing regulation amending Annex III, typically tabled within six to twelve months of a final opinion, depending on whether the change is classified as technical or political.

Brand owners distributing in Great Britain under the separate GB Cosmetics Regulation should expect the Office for Product Safety and Standards (OPSS) to track the EU position, with timelines dependent on the Northern Ireland Protocol alignment and the GB-specific risk assessment process.